Glymphatic System in Ocular Diseases: Evaluation of MRI Findings.
Journal
AJNR. American journal of neuroradiology
ISSN: 1936-959X
Titre abrégé: AJNR Am J Neuroradiol
Pays: United States
ID NLM: 8003708
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
02
12
2021
accepted:
03
05
2022
pubmed:
1
7
2022
medline:
12
7
2022
entrez:
30
6
2022
Statut:
ppublish
Résumé
There is growing evidence of leakage of gadolinium in an impaired blood-retina barrier. We investigated gadolinium enhancement in different eye compartments and correlated the enhancement with specific ophthalmologic diseases. In a prospective clinical study (ClinicalTrials.gov Identifier: NCT05035251), 95 patients (63 with and 32 without ophthalmologic disease) were examined before and after gadolinium administration (20 and 120 minutes) with heavily T2-weighted FLAIR. The cohort was divided according to the location of pathology into anterior and posterior eye compartment groups. Relative signal intensity increase in the anterior eye chamber, vitreous body with retina, optic nerve sheath, and the Meckel cave was analyzed and correlated with the final clinical diagnosis. In patients with a disorder in the anterior eye compartment, significant signal intensity increases were found in the central anterior eye chamber ( Increased gadolinium enhancement was found in the central and lateral anterior eye compartments and the vitreous body with retina in patients with anterior eye compartment disorders 20 and 120 minutes after contrast application, suggesting impairment of the blood-aqueous barrier. In patients with a disorder in the posterior eye compartment, pathologic enhancement indicated disruption of the blood-retinal barrier that allows gadolinium to diffuse into the vitreous body with retina from posterior to anterior, opposite to the known physiologic glymphatic pathway.
Sections du résumé
BACKGROUND AND PURPOSE
There is growing evidence of leakage of gadolinium in an impaired blood-retina barrier. We investigated gadolinium enhancement in different eye compartments and correlated the enhancement with specific ophthalmologic diseases.
MATERIALS AND METHODS
In a prospective clinical study (ClinicalTrials.gov Identifier: NCT05035251), 95 patients (63 with and 32 without ophthalmologic disease) were examined before and after gadolinium administration (20 and 120 minutes) with heavily T2-weighted FLAIR. The cohort was divided according to the location of pathology into anterior and posterior eye compartment groups. Relative signal intensity increase in the anterior eye chamber, vitreous body with retina, optic nerve sheath, and the Meckel cave was analyzed and correlated with the final clinical diagnosis.
RESULTS
In patients with a disorder in the anterior eye compartment, significant signal intensity increases were found in the central anterior eye chamber (
CONCLUSIONS
Increased gadolinium enhancement was found in the central and lateral anterior eye compartments and the vitreous body with retina in patients with anterior eye compartment disorders 20 and 120 minutes after contrast application, suggesting impairment of the blood-aqueous barrier. In patients with a disorder in the posterior eye compartment, pathologic enhancement indicated disruption of the blood-retinal barrier that allows gadolinium to diffuse into the vitreous body with retina from posterior to anterior, opposite to the known physiologic glymphatic pathway.
Identifiants
pubmed: 35772805
pii: ajnr.A7552
doi: 10.3174/ajnr.A7552
pmc: PMC9262072
doi:
Substances chimiques
Contrast Media
0
Gadolinium
AU0V1LM3JT
Banques de données
ClinicalTrials.gov
['NCT05035251']
Types de publication
Clinical Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1012-1017Informations de copyright
© 2022 by American Journal of Neuroradiology.
Références
Acta Physiol Scand. 1968 May-Jun;73(1):204-19
pubmed: 4175033
Fluids Barriers CNS. 2015 Jun 29;12:16
pubmed: 26118970
Magn Reson Med Sci. 2016;15(2):203-11
pubmed: 26597430
Magn Reson Med Sci. 2018 Apr 10;17(2):111-119
pubmed: 29367513
Int Ophthalmol. 2017 Jun;37(3):507-512
pubmed: 27405314
Biomed Res Int. 2017;2017:5123148
pubmed: 28948167
Neuroimage Clin. 2014 Aug 15;6:9-19
pubmed: 25379412
Eur Radiol. 2020 Aug;30(8):4633-4640
pubmed: 32179994
Invest Ophthalmol Vis Sci. 2019 Jun 3;60(7):2773-2780
pubmed: 31247084
Invest Radiol. 2019 Apr;54(4):229-237
pubmed: 30480554
Expert Opin Drug Deliv. 2016 Jul;13(7):963-75
pubmed: 27020469
Invest Radiol. 2021 Jul 1;56(7):425-432
pubmed: 33481460
AJNR Am J Neuroradiol. 2021 Dec;42(12):2160-2164
pubmed: 34824096
J Clin Neurosci. 2019 Oct;68:268-270
pubmed: 31204221
Invest Ophthalmol Vis Sci. 2020 Nov 2;61(13):24
pubmed: 33201186
Neurology. 2018 Mar 13;90(11):e915-e923
pubmed: 29438039
Fluids Barriers CNS. 2014 May 01;11:10
pubmed: 24817998